RE:RE:RE:Just a thoughtDo not click on that 2nd link as Nortons is blocking it as a malicious site. (IMO)This product is not months away.
This is a quote from VMs website(pretty plain)
"Voyageur is the only pharmaceutical company to have access to fullerene and vanadium at no sourcing cost because of its drug development agreement with Rain Cage. The agreement provides for Voyageur and Rain Cage to share future revenue from drug sales. Voyageur has rights for carbon imaging drug development and sales for North America. Cost of carbon and other minerals created by the Rain Cage technology are a by-product of carbon capture from fossil fuel emissions. Voyageur is in talks currently with potential drug development research firms to launch the drug development program. However, their clinical adoption is contingent upon continued research, clinical validation to confirm their safety and efficacy and regulatory approvals. The development of metallofullerene-based MRI contrast agents is a significant breakthrough that has the potential to be a game changer and disruptive to the medical imaging market. Gadolinium fullerene drugs can offer up to 50 times greater relaxivity than conventional gadolinium-based MRI contrast agents like Omniscan® and Magnevist®. https://pubmed.ncbi.nlm.nih.gov/19445504/. The unique structural advantages of metallofullerenes allow for lower dosing, enhanced image quality, and potentially fewer side effects."